| Imatinib mesylate for the treatment of gastrointestinal stromal tumor. | |
| | |
MedLine Citation:
|
PMID: 20469993 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of mesenchymal origin arising in the GI tract. These tumors are characterized by activating mutations of either receptor tyrosine kinase KIT or PDGFRA, which are found in 85% of cases. The introduction of imatinib mesylate (IM), which targets the kinases presenting with these molecular alterations, has dramatically changed the management of these rare tumors, which were resistant to conventional cytotoxic chemotherapy, both in advanced and localized phases. IM is orally available, has a favorable safety profile and induces partial responses and disease stabilization in up to 80% of patients with advanced GIST. Recently, IM was approved for the postoperative treatment of patients with completely resected localized GIST. |
| | |
Authors:
|
Philippe A Cassier; Jean-Yves Blay |
Related Documents
:
|
21660403 - Billateral polycystic kidneys in a girl with wagr syndrome. 20162573 - Strong expression of igf1r in pediatric gastrointestinal stromal tumors without igf1r g... 18614373 - Polyamine metabolism in maize tumors induced by ustilago maydis. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert review of anticancer therapy Volume: 10 ISSN: 1744-8328 ISO Abbreviation: Expert Rev Anticancer Ther Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-17 Completed Date: 2011-01-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101123358 Medline TA: Expert Rev Anticancer Ther Country: England |
Other Details:
|
Languages: eng Pagination: 623-34 Citation Subset: IM |
Affiliation:
|
Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials as Topic / methods Gastrointestinal Stromal Tumors / drug therapy*, enzymology* Humans Piperazines / pharmacology, therapeutic use* Protein-Tyrosine Kinases / antagonists & inhibitors*, metabolism Pyrimidines / pharmacology, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.10.1/Protein-Tyrosine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Correlation between cognitive impairment and cerebral hemodynamic disturbances on perfusion magnetic...
Next Document: Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.